An analysis of controlled correspondence between generic-drug manufacturers and FDA reveals patterns in questions about specific drug chemistry topics and the response to information provided in FDA guidance documents.
Min Li
Advertisement
Min Li, PhD is with the Center for Drug Evaluation and Research, FDA
Articles by Min Li
Advertisement
Latest Updated Articles
Regulatory Considerations for Controlled Correspondence Related to Generic Drug ChemistryPublished: September 1st 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Why Investment Strategies Matter for Advancing Pharmaceutical Technologies
2
PharmTech Weekly News Roundup – Week of November 3, 2025
3
AAPS PharmSci 360 2025: Trends in Bioanalysis
4
AAPS PharmSci 360 2025: The Role of LC–MS in Bioanalysis
5
